Related Experiment Videos
Thromboangiitis obliterans (Buerger's disease).
1Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY 10029, USA. jeffrey.olin@msnyuhealth.org
Current Opinion in Rheumatology
|December 14, 2005
Summary
Complete tobacco abstinence is crucial for preventing amputation in thromboangiitis obliterans (Buerger's disease). Research explores new therapies like cannabinoid receptor antagonists and therapeutic angiogenesis for this rare vasculitis.
Area of Science:
- Vascular Medicine
- Immunology
- Rheumatology
Background:
- Thromboangiitis obliterans (Buerger's disease) is a rare, nonatherosclerotic inflammatory vasculitis affecting small and medium arteries/veins.
- It primarily impacts the extremities, presenting distinct pathophysiology compared to other vasculitides.
Purpose of the Study:
- To familiarize physicians with the unique characteristics of thromboangiitis obliterans.
- To review current understanding and emerging therapeutic strategies for Buerger's disease.
Main Methods:
- Literature review focusing on pathophysiology, diagnosis, and treatment of thromboangiitis obliterans.
- Analysis of recent findings regarding endothelial dysfunction and biomarkers.
Main Results:
- Tobacco use is central to Buerger's disease; cessation is the only proven method to prevent amputation.
- Endothelial dysfunction and elevated anti-endothelial cell antibodies are observed.
- Emerging therapies include cannabinoid receptor antagonists and therapeutic angiogenesis, showing promise.
Conclusions:
- Studying rare diseases like thromboangiitis obliterans is challenging due to limited funding and patient numbers.
- Despite challenges, new therapeutic modalities offer hope.
- Complete tobacco cessation is paramount for preventing amputation in Buerger's disease patients.